Pharmaceutical industry

ERC Announces Publication of Positive Efficacy Data with Sitoiganap in Patients with Recurrent Glioblastoma

Retrieved on: 
Thursday, June 30, 2022 - 6:00am
Cell, Frontiers, Neuro, Patient, ERC, CEO, Glioblastoma, Brain, GLOBE, Gliosarcoma, Cancer, Disease, Mass flow (life sciences), Prognosis, Epitopoietic Research Corporation, Neoplasm, Toxicity, Doctor of Philosophy, Survival, Quality of life, Immunotherapy, Safety, Epitope, Recurrence, MD, Hope, Observation, Pharmaceutical industry, Medical imaging, Medicine

The authors reported striking efficacy and safety of a therapeutic vaccine SITOIGANAP administered to 21 patients with recurrent glioblastoma (rGBM).

Key Points: 
  • The authors reported striking efficacy and safety of a therapeutic vaccine SITOIGANAP administered to 21 patients with recurrent glioblastoma (rGBM).
  • Glioblastoma has a dismal prognosis with half of rGBM patients dying within 8 months of recurrence of the disease.
  • Data presented by the authors show that treatment with Sitoiganap (also called Gliovac or ERC1671) more than doubles median overall survival to 19.6 months.
  • Sitoiganap is for patients suffering from a grade IV glioma (glioblastoma and gliosarcoma) when all other traditional treatments have failed.

Tianda Pharmaceuticals Annual Results 2022

Retrieved on: 
Thursday, June 30, 2022 - 3:40am
Cloud, Efficiency, Current, Research, COVID, Medicine, R, YOY, Marketing, COVID-19, Growth, Industry, Trust, TCM, CDMO, Rehabilitation, CMO, Awareness, ID, Woman, Contract, Central Drugs Standard Control Organisation, ISO, Technology, Health, No, Certification, CSR, Farmer, Board, Kerala State Drugs and Pharmaceuticals Limited, BD, Medication, Method, Director, Fine chemical, Pharmaceutical industry, Group

HONG KONG, June 30, 2022 - (ACN Newswire) - Tianda Pharmaceuticals Limited (Tianda Pharmaceuticals or the Group, stock code: 0455.HK) is pleased to announce its annual results for the year ended 31 March 2022.

Key Points: 
  • HONG KONG, June 30, 2022 - (ACN Newswire) - Tianda Pharmaceuticals Limited (Tianda Pharmaceuticals or the Group, stock code: 0455.HK) is pleased to announce its annual results for the year ended 31 March 2022.
  • Innovation and R&D made steady progress with R&D expenses increasing 34.7% year on year (YOY) to HK$15.9 million.
  • With cash and cash equivalents of approximately HK$334.0 million as of 31 March 2022, the Group has sufficient financial resources to support its business development.
  • The new R&D and production base located in Jinwan, Zhuhai
    The Pharmaceuticals and medical technologies business revenue reached HK$396.1 million, an increase of 10.7% YOY.

CanariaBio Announces Milestone achievement of 50% patient enrollment in its Phase III FLORA-5 clinical study of its lead product oregovomab in front-line advanced ovarian cancer treatment

Retrieved on: 
Thursday, June 30, 2022 - 4:57am
Death, Patient, Biotechnology, HER2/neu, MUC1, Gynaecology, Trial of the century, Immunization, Cancer, Immunoglobulin G, Terminology, GOG, PSA, Risk, Overalls, Immunotherapy, Toxicity, Antibody, Oregovomab, Survival, Paclitaxel, FRCPC, Leadership, Safety, MH, Carboplatin, Drug combination, Ovarian cancer, Cancer immunology, Pharmaceutical industry

For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.

Key Points: 
  • For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.
  • Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.
  • Clinical and translational results were published in Gynecology Oncology 2020 156:523-529) and Cancer Immunology and Immunotherapy 2020 69: 383-397, respectively.
  • CanariaBio Inc. is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer.

Avantor Named Best Company for Upstream Processing and Single-Use Solutions at BMK 2022

Retrieved on: 
Thursday, June 30, 2022 - 2:42am
Science, Patient, Global health, LinkedIn, Research, Left, Laboratory, Award, Golden LEAF Biomanufacturing Training and Education Center, BMK, Biopharmaceutical, Organization, China Biologic Products, Safety, Twitter, Fine chemical, Pharmaceutical industry, Avantor, Facebook

Incheon, Korea, June 30, 2022 - (ACN Newswire) - Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, acquired awards for the best company in upstream processing and single-use solutions at the Biologics Manufacturing Korea (BMK) 2022 conference.

Key Points: 
  • Incheon, Korea, June 30, 2022 - (ACN Newswire) - Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, acquired awards for the best company in upstream processing and single-use solutions at the Biologics Manufacturing Korea (BMK) 2022 conference.
  • In single-use solutions, Avantor received the best company award for the third consecutive year.
  • Avantor was recognized for strengthening production capabilities and establishing an optimized supply chain in collaboration with global partners to respond to the growing need of biopharmaceutical manufacturers for single-use solutions.
  • Narayana Rao Rapolu, Vice President, Biopharma Asia Middle East & Africa for Avantor said, “Avantor's single-use solutions enable biomanufacturers to bring new therapies to market faster and improve global health.

CanariaBio Announces Milestone achievement of 50% patient enrollment in its Phase III FLORA-5 clinical study of its lead product oregovomab in front-line advanced ovarian cancer treatment

Retrieved on: 
Thursday, June 30, 2022 - 3:40am
Death, View, Patient, Biotechnology, HER2/neu, MUC1, Gynaecology, Trial of the century, Immunization, Cancer, Multimedia, Immunoglobulin G, Terminology, GOG, PSA, Risk, Overalls, Immunotherapy, Toxicity, Antibody, Oregovomab, Survival, Paclitaxel, FRCPC, Leadership, Safety, MH, Carboplatin, Drug combination, Ovarian cancer, Cancer immunology, Pharmaceutical industry

For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.

Key Points: 
  • For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.
  • Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.
  • Clinical and translational results were published in Gynecology Oncology 2020 156:523-529) and Cancer Immunology and Immunotherapy 2020 69: 383-397, respectively.
  • CanariaBio Inc. is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer.

Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Including Corporate Reorganization

Retrieved on: 
Thursday, June 30, 2022 - 3:00am
Patient, Research, TSX, GLOBE, Marketing, Growth, Company, Psilocybin, Mission statement, Spinout, Family, Drug development, Patent, Contract research organization, Efficiency, Depreciation, TSX Venture Exchange, Nasdaq, Travel, Exercise, Association, Pharmacokinetics, Wellness, Field trip, Concurrency, Intention, International Financial Reporting Standards, Acquisition, IAS, CEO, Ketamine, Lists of diseases, Substance abuse, DC, Toronto Stock Exchange, CRO, IFRS, NASDAQ, Board, Mental health, Drug discovery, Method, Anxiety, International, R, Depression, 1836 U.S. Patent Office fire, District, Reunion, PAT, Safety, Home Power, Pharmaceutical industry, Online gambling, Security (finance), Management, BC, Arrangement

In May, 2022, launched Field Trip at Home Powered by Nue Life, an advanced wellness platform for personalized, at-home psychedelic care.

Key Points: 
  • In May, 2022, launched Field Trip at Home Powered by Nue Life, an advanced wellness platform for personalized, at-home psychedelic care.
  • TORONTO, June 29, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, reported fiscal fourth quarter and full year 2022 results for the period ended March 31, 2022 and provided a business update.
  • Post quarter end, Field Trip announced the completion of its previously announced strategic review and the intention to complete a reorganization that will separate the Field Trip Discovery and Field Trip Health Divisions into two independent public companies (the Spinout Transaction).
  • Throughout the fiscal fourth quarter, the Company continued to implement operational improvements to reduce costs and increase throughput at its Field Trip Health Centers.

Hywin Holdings and FactSet Launch Global Health Care Index

Retrieved on: 
Thursday, June 30, 2022 - 3:00am
Ageing, Solution, USD, GLOBE, Index, Johnson & Johnson, COVID-19, Company, Industry, FDS, Forward-looking statement, Thermo Fisher Scientific, Terminology, FactSet, Technology, NYSE, HYW, Learning, SEC, Private Securities Litigation Reform Act, NASDAQ, Twitter, Pharmaceutical industry, Asset management, Risk management, Financial services, Pfizer

SHANGHAI, China and HONG KONG, June 30, 2022 (GLOBE NEWSWIRE) -- Hywin Holdings Ltd. ("Hywin Wealth", "Hywin", or the "Company") (NASDAQ: HYW), a leading independent wealth management service provider in China, and FactSet (NYSE: FDS) (NASDAQ: FDS), a global provider of integrated financial information, analytical applications, and industry-leading service, today announced the launch of FactSet Hywin Global Health Care Index (FHGHC) to enable global investors to better capture the investment opportunities within the healthcare industry.

Key Points: 
  • SHANGHAI, China and HONG KONG, June 30, 2022 (GLOBE NEWSWIRE) -- Hywin Holdings Ltd. ("Hywin Wealth", "Hywin", or the "Company") (NASDAQ: HYW), a leading independent wealth management service provider in China, and FactSet (NYSE: FDS) (NASDAQ: FDS), a global provider of integrated financial information, analytical applications, and industry-leading service, today announced the launch of FactSet Hywin Global Health Care Index (FHGHC) to enable global investors to better capture the investment opportunities within the healthcare industry.
  • With a maximum of 5% single-stock weighting, the FactSet Hywin Global Health Care Index represents a diversified and comprehensive benchmark of the global healthcare industry.
  • Hywin, as the source of idea for the index, provides value to clients through offering a learning platform to observe sub-sectors of global healthcare, its various business models and successful companies.
  • FactSet Hywin Global Health Care Index will be published on a daily basis and available on global financial media, data terminals, and broker platforms starting from July 1, 2022.

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Thursday, June 30, 2022 - 2:06am
Professional Services, Class Action Lawsuit, Ethics, FDA, Patient, Breast cancer, Company, Suite, Inflammation, Food, Certification, NYSE, Prostate cancer, NUVB, Food and Drug Administration, Uveitis, News, Eye, Security (finance), Pharmaceutical industry

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nuvation Bio Inc. (Nuvation or the Company) (NYSE: NUVB ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nuvation Bio Inc. (Nuvation or the Company) (NYSE: NUVB ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against First High-School, Upstart, Oscar, and Axsome and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, June 30, 2022 - 2:00am
Register, Acceleration, File, GLOBE, Prescription Drug User Fee Act, COVID-19, Growth, Company, Oscar Health, Risk, Annual report, New, Food, Upstart, Environment, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, NDA, CMC, FDA, Migraine, CRL, Student, Diplomacy, Exercise, First High-School Education Group, NYSE, Chemistry, IPO, Education, Defendant, Offering, Endpoint security, COVID, COVID-19 testing, Letter, Lidong, First, NASDAQ, MLR, News, Complaint, FHS, ADS, OSCR, U.S. Securities and Exchange Commission, Lists of schools in England, Form, CFO, Registration statement, Government, Neurological disorder, Tutoring, Animal, Renewable energy, Audit, Security (finance), Pharmaceutical industry, P.C

First High-School Education Group Co., Ltd. (NYSE: FHS)

Key Points: 
  • First High-School Education Group Co., Ltd. (NYSE: FHS)
    First High-School Education provides tutoring services and operates private high schools in Western China.
  • Then, on May 14, 2021, Chinas state council announced rules that it would further tighten regulations on compulsory education and training institutions.
  • For more information on the Axsome class action go to: https://bespc.com/cases/AXSM
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Verrica, Apyx, Waste Management, and Tupperware and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, June 30, 2022 - 2:00am
Waste management, FDA, Acquisition, Defendant, SMR, Negotiation, Energy Products Inc, Molluscum contagiosum, Endpoint security, Mergers and acquisitions, Waste Management (corporation), GLOBE, Advanced Energy, Failure, Company, Prospectus, Tupperware, Lists of schools in England, CMO, Disclosure, Food, LLC, Office of Inspector General, U.S. Department of Health and Human Services, NYSE, Coagulation, New Drug Application, U.S. Department of Justice Office of Legislative Affairs, NASDAQ, Tripura Merger Agreement, News, GFL Environmental, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DOJ, NDA, Tupperware Brands, Pharmaceutical industry, Animal, Renewable energy, Risk management, Audit, Bank, P.C, Note

In November 2021, Verrica resubmitted the NDA for VP-102, claiming [t]he resubmission addresses the successful resolution of inspection deficiencies at the manufacturing facility.

Key Points: 
  • In November 2021, Verrica resubmitted the NDA for VP-102, claiming [t]he resubmission addresses the successful resolution of inspection deficiencies at the manufacturing facility.
  • For more information on the Waste Management class action go to: https://bespc.com/cases/WM
    On May 4, 2022, Tupperware announced its financial results for the first quarter of 2022.
  • For more information on the Tupperware class action go to: https://bespc.com/cases/TUP
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.